Clinical Evaluation of Visual Field Change in Glaucoma: an Assessment of Different Models
The purpose of this observational study is to collect over time a series of data in patients with glaucoma in order to evaluate different approaches in defining the progression of this pathology. These data will be collected in repeated visits over a 36-months follow-up period. At each visit, the COMPASS fundus perimet
| Condition(s) | Glaucoma |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The purpose of this observational study is to collect over time a series of data in patients with glaucoma in order to evaluate different approaches in defining the progression of this pathology. These data will be collected in repeated visits over a 36-months follow-up period. At each visit, the COMPASS fundus perimeter and the Humphrey Field Analyzer (HFA) perimeter will be used to assess retinal functionality; an Optical Coherence Tomography (OCT) examination will also be performed to evaluate and obtain clinical information about the structure of the retina. |
| Who can participate | Inclusion Criteria: * Glaucomatous optic nerve head in both eyes; * Age between 40 and 90 years; * Best Corrected Visual Acuity ≤ 0.3 \[logMar\]; * Spherical refraction between -6D and +6D; * Astigmatism between -2D and +2D. Exclusion Criteria: * Any ocular surgery, except for: uncomplicated cataract surgery and/or glaucoma surgery in both eyes performed within 6 months before enrollment; * Any ocular pathology that can affect visual field other than glaucoma; * Use of any drug that can interfere with the correct execution of perimetry or that would produce visual field loss; * Inability to obtain reliable perimetric examinations; * Patients with advanced glaucoma for whom, according to the clinician, a 24-2 grid is not advisable to correctly monitor the patient. |
| Ages | 40 Years to 90 Years |
| Sex | All |
| Lead sponsor | Centervue SpA |
| Locations | Milan, Milano, Italy; Roma, Roma, Italy |
| Start date | 2022-05-06 |
| NCT ID | NCT05801471 |
| Official listing | https://clinicaltrials.gov/study/NCT05801471 |